BACKGROUND: Multicenter precision oncology real-world evidence requires a substantial long-term investment by hospitals to prepare their data and align on common Clinical Research processes and medical definitions. Our team has developed a self-assessment framework to support hospitals and hospital networks to measure their digital maturity and better plan and coordinate those investments. From that framework, we developed PRISM for Cancer Outcomes: PR: agmatic I: nstitutional S: urvey and benchM: arking. OBJECTIVES: The primary objective was to develop PRISM as a tool for self-assessment of digital maturity in oncology hospitals and research networks; a secondary objective was to create an initial benchmarking cohort of >25 hospitals using the tool as input for future development. METHODS: PRISM is a 25-question semiquantitative self-assessment survey developed iteratively from expert knowledge in oncology real-world study delivery. It covers four digital maturity dimensions: (1) Precision oncology, (2) Clinical digital data, (3) Routine outcomes, and (4) Information governance and delivery. These reflect the four main data types and critical enablers for precision oncology research from routine electronic health records. RESULTS: During piloting with 26 hospitals from 19 European countries, PRISM was found to be easy to use and its semiquantitative questions to be understood in a wide diversity of hospitals. Results within the initial benchmarking cohort aligned well with internal perspectives. We found statistically significant differences in digital maturity, with Precision oncology being the most mature dimension, and Information governance and delivery the least mature. CONCLUSION: PRISM is a light footprint benchmarking tool to support the planning of large-scale real-world research networks. It can be used to (i) help an individual hospital identify areas most in need of investment and improvement, (ii) help a network of hospitals identify sources of best practice and expertise, and (iii) help research networks plan research. With further testing, policymakers could use PRISM to better plan digital investments around the Cancer Mission and European Digital Health Space.

Biobank Innsbruck Innsbruck Austria

Charité Universitätsmedizin Berlin Berlin Germany

Cliniques Universitaires Saint Luc Brussels Belgium

Data Factory and Analytics Department Institut de Cancérologie de l'Ouest Nantes Angers France

Data Office Institut Curie Paris France

DIGICORE Bruxelles Belgium

Fondazione 1 R C C S Policlinico San Matteo Pavia PV Italy

Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

Institute of Oncology Ljubljana Ljubljana Slovenia

Instituto Português de Oncologia do Porto Francisco Gentil Porto Portugal

IQVIA London United Kingdom

IRCCS Istituto Nazionale Tumori Regina Elena Rome Italy

IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori Meldola Italy

IRCCS San Raffaele Scientific Institute Milan Italy

Karolinska Comprehensive Cancer Center Stockholm Sweden

Leeds Teaching Hospitals NHS Trust Leeds United Kingdom

Maastricht Comprehensive Cancer Center Maastricht The Netherlands

Masaryk Memorial Cancer Institute Brno Jihomoravský Czechia

Oslo University Hospital Cancer Center Oslo Norway

Sestre Milosrdnice University Hospital Zagreb Croatia

START Madrid CIOCC Centro Integral Oncológico Clara Campal Madrid Spain

Tartu University Hospital Tartu Tartumaa Estonia

Tays Cancer Centre Pirkanmaa Finland

Trinity St James's Cancer Institute Dublin Ireland

University Cancer Center Frankfurt University Hospital Goethe University Frankfurt Germany

University Hospital San Luigi Gonzaga of Orbassano Orbassano TO Italy

Vall d'Hebron University Hospital Barcelona Spain

Vejle Hospital University of Southern Denmark Vejle Denmark

Appl Clin Inform. 2024 Aug;15(4):e1. doi: 10.1055/s-0044-1792139. PubMed

See more in PubMed

Ekman S, Griesinger F, Baas P et al.I-O Optimise: a novel multinational real-world research platform in thoracic malignancies. Future Oncol. 2019;15(14):1551–1563. PubMed

Salles G, Bachy E, Smolej L et al.Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia. Ann Hematol. 2019;98(12):2749–2760. PubMed PMC

Palomba M L, Ghione P, Patel A R et al.A comparison of clinical outcomes from updated Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL) Blood. 2021;138(01):3543.

HIMSS HIMSS Maturity Models: Models for Digital Health Transformation. Accessed July 10, 2024 at: https://www.himss.org/what-we-do-solutions/maturity-models. (05/07/2024)

European Commission Europe's Beating Cancer planAccessed June 20, 2024 at:eu_cancer-plan_en_0.pdf(europa.eu)

European Commission EU Mission: Cancer (europa.eu) Accessed July 10, 2024 at: https://research-and-innovation.ec.europa.eu/funding/funding-opportunities/funding-programmes-and-open-calls/horizon-europe/eu-missions-horizon-europe/eu-mission-cancer_en (05/07/2024)

Mahon P, Chatzitheofilou I, Dekker A et al.A federated learning system for precision oncology in Europe: DigiONE. Nat Med. 2024;30(02):334–337. PubMed

Boomsma F, Van Harten W, Oberst Set al.OECI. Accreditation and Designation User Manual V. 2.0. User manual of A&D ProgrammeAccessed June 202, 2024 at:oeci.eu